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Background. The PRECISE-DAPT and PARIS risk scores (RSs) were recently developed to help 
clinicians at individualizing the optimal dual antiplatelet therapy duration (DAPT) after 
percutaneous coronary intervention (PCI). Nevertheless, external validation of these RSs it has not 
yet been performed in ACS (acute coronary syndrome) patients treated with prasugrel or ticagrelor 
in a real- world scenario.
Methods: 4,424 ACS patients who underwent PCI and survived to hospital discharge, from 
January 2012 to December 2016 at 12 European centers, were included. PRECISE-DAPT and 
PARIS bleeding RS, as well as PARIS ischemic RS, were computed, and their performance at 
predicting major bleeding (MB; BARC type 3 or 5) and ischemic events (MI and stent thrombosis) 
during follow up was compared. 
Results: After a median follow-up of 14 (interquartile range 12-20.9) months, 83 (1.88%) patients 
developed MB and 133 (3.0%) suffered an ischemic episode. PRECISE-DAPT performed better 
than PARIS bleeding RS (c-statistic= 0.653 vs. 0.593; p= 0.01 for comparison) in predicting MB. 
The RSs performance for MB prediction remained consistent in STEMI patients (c-statistic= 0.632 
vs 0.575) or in those treated with prasugrel (c-statistic = 0.623 vs 0.586). 
PARIS ischemic RS exhibited modest but superior discrimination in predicting ischemic 
complications as compared to PRECISE-DAPT (c-statistic= 0.604 vs 0.568 p= 0.05 for 
comparison). 
Conclusion: Our data provide support to the use of PRECISE-DAPT in MB risk stratification for 
patients receiving DAPT in form of aspirin and prasugrel or ticagrelor whereas the PARIS ischemic 
RS has potential to complement the risk prediction with respect to ischemic events.
 






























































Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (P2Y12i) is the 
standard of care in patients treated with percutaneous coronary intervention (PCI) and stent 
implantation. Yet, the most appropriate DAPT duration, especially in patients at high bleeding risk 
with prior acute coronary syndrome (ACS) remains a subject of intense controversy. 
The originally proposed “one-fits-all” strategy based on an at least twelve months regimen 
of DAPT has been questioned and a tailored treatment duration informed by the individual 
ischemic and bleeding risks has been more recently advocated 1–4. 
The PRECISE-DAPT and PARIS risk scores (RSs) have been recently developed to help 
physicians in stratifying post-discharge bleeding and ischemic risk in patients treated with DAPT 
after PCI5,6. Although both scores demonstrated a moderate predictive ability, the European 
Society of Cardiology (ESC) DAPT focused update exclusively endorsed, with a class IIb 
recommendation, the use of PRECISE-DAPT score, in view of a gap in knowledge whether PARIS 
RS improves the decision making on DAPT duration.  
However, the recommendation of the ESC regarding the use of PRECISE-DAPT is based 
on a single study where patients were largely treated with aspirin and clopidogrel5. Therefore, 
further investigating the predictive capability and reliability of PRECISE-DAPT seems necessary 
before generalizing its use to other populations with different clinical features, health systems and 
more contemporary medications. In addition, PRECISE-DAPT was derived from clinical trial 
patients, at variance with the PARIS RSs, which was developed from registry patients.
We sought to evaluate and compare the external validity of PRECISE-DAPT and PARIS 































































The design and patient population of RENAMI (REegistry of New Antiplatelet therapy in 
Myocardial Infarction) was comprehensively described elsewhere7. Briefly, in RENAMI dataset, 
consecutive ACS patients recruited at 12 European centers from January 2012 to December 2016 
were included (supplementary appendix).  The RENAMI registry included all comer patients with 
a final diagnosis of ACS: unstable angina (UA), non ST-segment elevation myocardial infarction 
(NSTEMI), or ST-segment elevation myocardial infarction (STEMI), aged at least 18 years, who 
consented for participation in the study. All patients underwent in-hospital coronary angiography 
and PCI with stent implantation followed by aspirin and either ticagrelor or prasugrel, at discretion 
of the treating physician. All patients were discharged with DAPT (aspirin plus ticagrelor or aspirin 
plus prasugrel). Excluded patients from the present analysis were those who experienced any 
adverse event defined as major bleeding (MB), new MI, stent thrombosis (ST), cardiovascular 
death or death for any causes during the index hospitalization. The institutional review board of 
each center approved the study protocol.
Objectives
We sought to evaluate and compare the performance of PRECISE-DAPT and PARIS RSs 
at predicting post-discharge MB and ischemic events (MI and ST), in the overall cohort and in 
subgroups of interest, including STEMI vs. NSTEACS (UA and NSTEMI), ticagrelor vs. prasugrel, 
and according to different DAPT durations (< 12 months, 12 months, and > 12 months).
Follow-up and definitions
The follow-up was conducted at each single center with at least two in contact visits within 
the first year after inclusion in order to assess the occurrence of any relevant clinical events and 
assess drug-adherence. Data on vital status (alive or dead) and events during follow-up were 
obtained from hospital clinical data records, as well as from administrative records (vital statistics 





























































made with patients or their relatives and primary care physicians in particular cases for which 
information was not available.
Follow-up time was ended by DAPT duration; therefore, the events recorded (MB or MI/ST 
or cardiovascular death) occurred while patients were on DAPT. We only considered the first MB 
or MI/ST episodes occurred during follow-up. Therefore, in patients who had developed more than 
one complication, the follow-up time was ended at the time of the first of the prior complications. 
Major bleeding was defined as those fulfilling type 3 or type 5 BARC criteria8. Ischemic 
events were defined as a composite of new MI or stent thrombosis or cardiovascular death. A new 
MI was defined according to the third definition of myocardial infraction9. ST was defined according 
to Academic Research Consortium criteria10. Cardiovascular death includes deaths that result from 
an MI, sudden cardiac death, death due to heart failure, death due to stroke, death due to 
cardiovascular procedures. 
Risk scores calculation
PRECISE-DAPT and PARIS were calculated in each patient on the basis of the original 
definitions used in their development cohorts (Supplementary Table 1-2, Supplementary Figure 
1)5,6. PRECISE-DAPT assigns patients into four risk strata (very low: ≤10, low: 11-17, moderate: 
18-24, and high: ≥25 points), whereas PARIS bleeding risk score categorizes patients into three 
risk groups (low: <3, moderate: 3-7, and high: ≥8 points). PARIS ischemic risk score also 
categorized patients into three strata but with different cut points: low: < 2; intermediate: 3-4: and 
high: ≥5 points. 
To enable comparisons between the PRECISE-DAPT and PARIS risk classification 
systems we categorized all patients into three risk strata by considering the very low and low risk 





























































Data presentation and statistical analysis
Baseline and clinical characteristics of the RENAMI external validation population, and the 
derivation cohorts of the PRECISE- DAPT and PARIS scores are presented as mean ± standard 
deviation (SD) and medians (interquartile ranges [IQR]) for continuous variables, and as 
proportions for categorical variables.
The total RSs, as continuous variables, were entered into separate Cox regression models 
to test their association with ischemic and MB events. The ability to separate high-risk from lower 
risk patients was visually appraised by generation of Kaplan-Meier curves for events of interest and 
compared using the log-rank test. The magnitude of the association between each of the three 
predefined risk categories from the RSs was calculated and expressed as hazard ratios (HR) with 
their 95% confidence intervals (95% CI); the low risk category was considered as a reference 
category.
The predictive capacity of the RSs was tested by means of indices of discrimination and 
calibration. To assess discrimination, using the total RS as a global prognostic indicator, we 
calculated and compared the Harrell c-statistic for censored time-to-event data, for both scores11.  
Calibration was computed using the Grønnesby and Borgan χ2 test, and plotted observed vs. 
predicted outcomes.
The time-frame of 12 months was used to assess the ability of both scores to predict outcomes 
over the first year, in order to decide to stop or to prolong DAPT. The Kaplan-Meier curves end at 
18 months in order to show the whole study follow-up.
We further assessed  the  net  reclassification  improvement index (NRI)12. For the NRI calculation, 
individuals were compared based on their bleeding and ischemic risk using the three categories of 
the two RSs. Since the probability of MB and MI/ST was set at different thresholds in the 
respective risk categories of PRECISE-DAPT and PARIS, we further analyzed possible 
improvement in the discrimination ability of one score vs. the other by means of the “categoryless” 





























































suggest cfNRI greater than 0.6 indicates a strong contribution and NRI(>0) between 0.2 and 0.6 
implies moderate improvement13,14.
Decision curve analyses (DCA) were also used to quantify the net benefit of the prediction 
scores; the higher the net benefit, the better the RS, in terms of clinical usefulness. The theoretical 
range of net benefit is from negative infinity to the incidence of disease. 
Finally, we considered the average daily difference between ischemic and bleeding events 
according to the risk categories of PRECISE-DAPT and PARIS risk scores limiting the analysis to 
the first event occurring (MB, MI, death, ending of DAPT). The average daily rate for a given 
interval was defined as the total number of events in that interval divided by the total number of 
patient-days of follow-up (number of patients multiplied by how many days each patient was at risk 
in that given period).
A two-sided p<0.05 was considered statistically significant. All statistical analysis was 




The baseline characteristics of the RENAMI population are summarized in table 1. Patients 
in RENAMI were younger and less frequently females, as compared with those used to generate 
the the PRECISE-DAPT and PARIS RSs. 
Most of patients in this study had STEMI and largely received drug eluting stent implantation. All 
patients received DAPT in form of either prasugrel or ticagrelor.  A total of 22.3%, 50.1% and 
27.6% of the patients in the RENAMI study received DAPT for less then 12 months, 12 months or 





























































The PRECISE-DAPT varied from 0 to 75 points (17±10 points), and 20.4% of patients were 
categorized as having high risk of bleeding. (Figure 1). In contrast, the PARIS bleeding RS values 
ranged from 0 to 10 points (3±2 points), with only 3.9% of patients fulfilling the high-risk category 
(Figure 1). 
The PARIS ischemic score ranged from 1 to 13 points (4±2 points) with 23.1% of the patients 
being categorized at high ischemic risk. 
Bleeding and ischemic risk assessment based on the RSs classification systems
After a median follow-up of 14 (IQR: 12-20.9) months, 83 (1.88%) patients developed MB 
and 133 (3.0%) suffered an ischemic episode. Median time for first MB was 5.0 (IQR 1.6-9.4) 
months, and for ischemic events 9.6 (IQR 2.6-16.9) months.  The Kaplan-Meier curves based on 
risk categories assigned by each score for the occurrence of MB are shown in Supplementary 
Figure 2. Both PRECISE-DAPT and PARIS bleeding RSs showed significant predictive capability 
(log-rank test, p<0.01). The observed bleeding rates for the two scores increased monotonically 
from low- to high-risk categories. However, Kaplan-Meier curves diverged in a more pronounced 
way with PRECISE-DAPT (χ² values were 23 [p<0.001] for PRECISE-DAPT vs. 10 [p=0.002] for 
PARIS). After an adjustment for potential clinically relevant confounders (age, sex, hypertension, 
diabetes mellitus, history of malignancies, prior-MI, prior-bleeding, anemia, creatinine clearance,  
ACS or non-ACS clinical presentation, DES or BMS, enrolling center), with Cox regression models 
both PRECISE DAPT and PARIS bleeding RSs confirmed their independent ability to predict MBs 
on the basis of their risk categories (PRECISE DAPT moderate risk HR: 2.56 CI: 1.52 – 4.31 p < 
0.0001; PRECISE DAPT high risk HR: 4.01 CI: 2.57 – 6.28 p < 0.0001 and PARIS bleeding 
moderate risk HR: 2.11 CI: 1.39 – 3.21 p < 0.0001; PARIS bleeding high risk HR: 5.78 CI: 3.16 – 
10.55 p < 0.0001). Similar results were observed for the prediction of ischemic events (PRECISE 





























































1.88 – 5.04 p < 0.0001 and PARIS ischemic moderate risk HR: 2.00 CI: 1.31 – 3.07 p = 0.001; 
PARIS ischemic high risk 2.60 CI: 1.68 – 4.02 p < 0.0001).
Consistent findings were noted for the predictive value of both RSs in predicting MI/ST or 
cardiovascular death (supplementary materials Figure 3-4)
Discrimination 
Both PRECISE-DAPT and PARIS bleeding scores, as continuous variables, were better 
than the chance for predicting MB. However, the PRECISE-DAPT performed better than the 
PARIS bleeding RS at c-statistics (c-statistic= 0.653, [95%CI: 0.59-0.71]; c-statistic: 0.593, [95%CI: 
0.528-0.658]; p=0.01 for correlated c-statistic values comparison). 
In contrast, the discriminative capacity of PARIS ischemic RS, as compared to PRECISE-DAPT, 
was slightly higher (c-statistic = 0.604, [95%CI:  0.550-0.657] and 0.568 [95%CI: 0.509-0.626]; 
p=0.05 for correlated c-statistics values comparison).
The c-statistic values for different DAPT duration, clinical presentation, P2Y12 inhibitors, 
age and serum creatinine level are summarized in table 2. Briefly, the PRECISE-DAPT score was 
able to predict MB reasonably well and better than the PARIS bleeding RS in almost all analyzed 
sub-categories but its discriminative capacity for MB was found to be slightly reduced in patients 
treated with prasugrel, patients > 75 years and in patients with STEMI at presentation compared to 
those treated with ticagrelor, patients < 75 years and those with NSTEACS at presentation. Finally, 
PARIS ischemic RS was better than PRECISE DAPT in predicting ischemic events in all subgroup 
analyses with the exception of patients treated with ticagrelor in which the discrimination 
performance of the scores is almost the same.
 Calibration 
Calibration of observed against predicted MB was good for both RSs, although PRECISE 





























































bleeding RS. The calibration of PRECISE DAPT for observed against predicted ischemic events 
was suboptimal if compared with PARIS ischemic risk score as shown in Supplementary figure 5. 
In the figure, for each bin, the y-value is the proportion of true outcomes, and x-value is the mean 
predicted probability. Therefore, a well-calibrated model has a calibration curve that hugs the 
straight line y=x (blue line). The red points identify the observed probability of events based on the 
estimate of the score, so that if they are above the blue line they indicate that the score 
underestimates, and if they are below the blue line it indicates that the score overestimate.
Average daily rate events
PRECISE DAPT was able to predict the average daily difference between bleeding and ischemic 
events better than PARIS risk scores in all the three risk categories in the first year as shown in 
supplementary materials Figure 6. In particular, the average daily difference of events followed 
the risk categories stratification for PRECISE DAPT whereas wide overlap between risk categories 
and observed average daily rate events was noted for the two PARIS risk scores. 
Decision curves analyses for MB
Figure 2 compares the decision curves from classifying individuals using the PRECISE 
DAPT and PARIS bleeding RSs, assuming all patients will bleed (all positive or all are at high risk 
of bleeding), and assuming all patients as if none will bleed (all negative or all are at low risk of 
bleeding; horizontal line at 0). The DCA showed that the use of PRECISE DAPT is superior to 
PARIS bleeding RS at a risk threshold of ≥2%. PARIS bleeding RS did not prove to be 
advantageous, as compared to no use of the score, at a risk threshold of ≥3%, whereas PRECISE-
DAPT RS continued to stratify the bleeding risk until a threshold of 10% MB risk. The net benefit 
analysis for MB is summarized in Supplementary Table 3. The PRECISE DAPT showed superior 
predictive capability for MB events as opposed to the PARIS bleeding RS with a moderate 
improvement on risk prediction even when using a category-free NRI = 0.41 (95% CI: 0.20-0.65)
.DISCUSSION   





























































1) The PRECISE DAPT and PARIS bleeding RS perform moderately well in predicting MB 
in patients treated with ticagrelor or prasugrel in the first fourteen months after discharge. 2) 
PRECISE DAPT is significantly superior to PARIS bleeding RS for predicting MB. 3) The 
performance of both the RSs is consistent in all the subgroups included in the analysis. 4) PARIS 
ischemic RS is slightly better than PRECISE DAPT in predicting ischemic events.
There is an emerging need to focus on the trade off between ischemic and bleeding risks 
when treating contemporary patients with prolonged potent anti-thrombotic medications. in order to 
maximize the benefit and avoid the risks. The ischemic risk is progressively decreasing in the last 
years thanks to a great technological improvement of the stents and of PCI techniques15. At the 
same time, the use of more potent anti-platelets therapies in ACS patients and to the ageing of 
patients undergoing routine treatment, the bleeding events have become prevalent and they are 
able to dramatically affect the prognosis of our patients16–19.
Costa et al. and Baber et al. generated new models to better predict the incidence of MB 
and ischemic events in the first 12 or 24 months of treatment respectively, overcoming the 
limitations of previous studies, which mainly focused on in hospital events. The PRECISE DAPT 
modeled exclusively the bleeding risk and found that a score ≥ 25 points may be used in the 
decision-making of shortening DAPT duration to avoid bleeding. It was validated in patients 
enrolled in the PLATO study and in the Bern PCI registry (both ACS and stable angina) and 
showed superiority in the discrimination and reclassification performance respect to the PARIS 
bleeding RS.
In our study we tested the performance of PRECISE DAPT and PARIS RSs in a real-world 
registry with characteristics different from the derivation cohorts. First, all our patients were ACS 
with more than fifty percent of those presenting STEMI and were treated with prasugrel or 
ticagrelor. Yet, both bleeding RSs demonstrated a reasonable discriminative capacity to predict 
MB, hence confirming the results of previous studies, which were largely undertaken in patients 





























































We found that PRECISE DAPT was superior to PARIS bleeding RS in predicting MB. 
Despite similar results in the risk stratification of our population, the discrimination power, the 
average daily difference between bleeding and ischemic events and net benefit of PRECISE DAPT 
was superior particularly in the first year of follow-up. These results are consistent with the study of 
Costa et al5. 
A recent study of Abu-Assi et al provided opposite results in terms of performance of the 
two bleeding RSs considered20. This could be due to some differences in the baseline 
characteristics between the prior study and this cohort. Patients included in the RENAMI study 
were treated with prasugrel or ticagrelor, while in the study by Abu-Assi et al the majority of 
patients received clopidogrel; moreover, twenty percent of the patients of Abu-Assi et al were 
treated with a bare metal stent and data on the DAPT duration was not taken into account20. Taken 
all together, the prior study seems less generalizable to a population treated with the current 
standard of care and this could explain the different performance of bleeding RSs observed.    
Of note, in our study, the use of both bleeding RSs was superior to the strategies of not 
using the RSs for bleeding risk classification, as observed in the DCA. This means that the use of 
PRECISE-DAPT and PARIS bleeding RS is of clinical value to drive clinical decisions in bleeding 
risk stratification. Moreover, our work confirms the previous results from Raposeiras Roubin et al. 
on the utility of the PARIS RSs but shows that the PRECISE DAPT score is even better. In fact, 
over a risk score threshold of the 3% the PARIS bleeding RS failed to demonstrate a benefit over 
the strategy of not using a RS. For this reason, our observations strengthen the recommendation 
of the recent ESC position paper on anti-platelet therapy who recommend to use PRECISE DAPT 
score in bleeding risk stratification1. 
Due to the great difference in baseline characteristics between RENAMI cohort and the 
derivation cohorts of the PRECISE DAPT and PARIS RSs, we appraised the accuracy in predicting 
bleeding and ischemic events in different patient subgroups. We found a modest reduction in the 
accuracy of predicting MB events of PRECISE DAPT and PARIS bleeding RS in particular among 





























































three cohorts, the accuracy of both the scores was slightly reduced compared to the general 
population but overall, as showed in Table 2, the discrimination capacity is consistent in all the 
subgroups included in the analysis. The reduction in the discrimination ability of PRECISE DAPT 
score in patients treated with prasugrel was already shown by Costa et al. and is probably related 
to the average low bleeding profile of patients treated with prasugrel (< 75 years, > 60 kg and 
without previous intracranial bleedings)5. Finally, our analysis confirmed that the accuracy of 
bleeding risk scores decrease in elderly population as already shown in a previous study22.
The ischemic events prediction of PRECISE DAPT score is largely insufficient which is a 
consistent observation with the fact that this model was purely generated for bleeding prediction 
purposes.
The current results endorse the implementation of PRECISE DAPT score in the clinical 
practice as novel tool, particularly within the first year after intervention, to balance the bleeding 
and ischemic risks as shown by our average daily difference events analysis. The PRECISE-DAPT 
score allows selecting patients who derive benefit from a short DAPT (3 or 6 months) as well as 
those who should be treated with DAPT as long as possible, which is in keeping with current 
European guidelines1. On the other hand, the use of the PARIS risk scores does not seem to 
provide clinicians with clear risk stratification information due to some degree of overlap among 
different risk strata for bleeding and ischemic events. 
LIMITATIONS
This study has several limitations. This was a retrospective observational study, so we cannot rule 
out the presence of selection bias and unmeasured confounding factors. Moreover, we used 
treatment at discharge as a principle of intention-to-treat analysis, as we did have data on DAPT 
duration during follow-up. However, this principle was also applied in the PLATO and Bern PCI 
external validation cohorts used in the development of the PRECISE-DAPT score, and in the 





























































and in PARIS, in contrast to PRECISE-DAPT where bleeding definitions were based on TIMI 
criteria. This point could have affected the comparability of the scores. However, BARC bleeding 
criteria were also used as an alternative bleeding definition in the external validation cohorts of 
PRECISE-DAPT. Additionally, BARC bleeding criteria are currently considered the standard 
bleeding definition. Finally, Costa et al. showed a lower discrimination of PRECISE-DAPT score in 
patients treated with proton pump inhibitors (PPI); these medications are very important to reduce 
gastro intestinal bleedings in patients treated with DAPT, unfortunately we did not collect 
systematically the PPI treatment in our database and we are not able to provide any analysis on 
the influence of PPI in the performance of the RSs included in the analysis. 
CONCLUSION
Our data provide support to the use of PRECISE-DAPT in MB risk stratification for patients 
receiving DAPT in form of aspirin and prasugrel or ticagrelor whereas the PARIS ischemic RS has 
potential to complement the risk prediction with respect to ischemic events.
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Supplementary Table 3. Net benefit of using the PRECISE-DAPT and PARIS scores compared to 





Net benefit of assuming 
all as low risk
Net benefit of assuming 
all as high risk
Net benefit of using 
PRECISE-DAPT
Net benefit of 
using PARIS
1 0% 0,9% 0,9% 0,9%
2 0% -0,09% 0,38% 0,25%
3 0% -1,07% 0,08% 0%
Note: net benefit at different risk thresholds is calculated as {true-positive classifications – [% risk 
threshold/(100 − % risk threshold) × false-positive classifications]}/total number of participants.
The number of additional true positives per 100 patients the risk scores can identify without 
additional false positives, is calculated as follows: (% net benefit of using the score of interest – % 
net benefit of the alternative strategy in question)/[% risk threshold/100 − risk threshold]). This 
value is the equivalent to the reduction in false positive without a decrease in the number of true 




























































Figure 1. Patients risk class in the RENAMI registry using the PRECISE-












Figure 4: Decision curves for the PRECISE DAPT and PARIS bleeding RS derived 








Number of patients 4424 14963 4190
Age (mean ± SD) 60.9 ± 11.5 ---* 63.6±11.0
Age (median (IQR)) 61.0 (53-69) 65.0 (56.9-73) ---*
Female, % 20.8 29.5 25.4
Weight, Kg 80.1  ± 13.8 74.0 (65-84) ---*
BMI (mean ± SD) 27.4  ± 4.1 ---* 29.3±5.5
BMI median (IQR)) 27 (25.0 – 29.0) ---* ---*
Active smoking, % 29.1 28 17.8
Hypertension (%) 54 71.9 81.4
Diabetes Mellitus (%) 29.9 27.8 34.1
LVEF (mean ± SD) 51.2  ± 9.4 ---* ---*
Peripheral vascular disease,% 3.6 10.4 8
Prior MI,% 16.5 19.8 24.9
Prior PCI,% 17.9 ---* 41.9
Prior CABG,% 0.9 ---* 14.4
Prior stroke,% 5.2 3.6 3.5
Prior Bleeding,% 2.4 1.9 ---*
Malignancy,% 4.5 ---* ---*
UA,% 9 22.7 29.9
NSTEMI,% 33 14 7.9
STEMI,% 58 18.9 ---*
Haemoglobin (mean ± SD) 14.1  ± 1.3 ---*
Haemoglobin (median (IQR)) 14 (13.2 – 14.5) 13.8 (12.7-14.9) ---*
Anaemia,% 1.9 ---* 15
WBC count (103 units/μL) 
(mean ±SD)
10602  ± 1381 ---* ---*
WBC count (103 units/μL) 
(median (IQR))
10.600
 (8.200 – 12.335)
7.800 (6.300-10.200) ---*
CrCl (mL/min) (mean ±SD) 96.7  ± 37.3 79.1 (60.8-98.0) ---*
CrCl (mL/min) (median (IQR)) 93 (71-118)
CrCl <60 mL/min, % 15.9 17.8
DES,% 93 87.2 100
BMS,% 7 12.8 0
Treatment at discharge
Aspirin,% 99.9 98.7
Clopidogrel,% 0 87.7 92.1
Prasugrel,% 39 7.6 6.2
Ticagrelor,% 61 3.9 0
Statin,% 51 89.4
ACE inhibitors/ARB II,% 34 66.7
Β-blocker,% 37 74.3
Table 1: Baseline characteristics. LVEF= left ventricle ejection fraction. MI= myocardial infarction. PCI= 
percutaneous coronary intervention. CABG= coronary artery bypass graft. UA= unstable angina. NSTEMI= 
non-ST segment elevated myocardial infarction. STEMI= ST segment elevated myocardial infarction. 
ACE/ARB: ACE inhibitor or angiotensin-II receptor blocker.  *Data not reported in the original study.
Discrimination capacity (C-statistic) for MB risk prediction by different DAPT durations 
PRECISE DAPT PARIS bleeding RS
Overall, nº of MB events= 83 0.653 (0.591-0.714) 0.593 (0.528-0.658)
12 months, nº of MB events= 44 0.624 (0.530-0.718) 0.526  (0.432-0.620)
More than 12 months, nº of MB 
events= 14
0.648  (0.491-0.805) 0.666  (0.514-0.818)
Less than 12 months, nº of MB 
events= 25
0.689  (0.596-0.782) 0.633 (0.517-0.749)
Discrimination capacity (C-statistic) for ischemic risk prediction by different DAPT durations
PRECISE DAPT PARIS ischemic RS
Overall, nº of ischemic events= 133 0.568 (0.509-0.626) 0.604 (0.550-0.657)
12 months; nº of ischemic events= 54 0.525 (0.423-0.628) 0.571  (0.492-0.650)
More than 12 months; nº of ischemic 
events= 40
0.537 (0.431-0.643) 0.656 (0.564-0.755)
Less than 12 months nº of ischemic 
events= 39
0.648 (0.550-0.745) 0.597 (0.492-0.702)
Discrimination capacity (C-statistic) for MB risk prediction in STEMI patients
PRECISE DAPT PARIS bleeding RS
nº of MB events in STEMI: 48 0.632 (0.547-0.717) 0.575 (0.487-0.663)
Discrimination capacity (C-statistic)  for ischemic risk prediction in STEMI patients 
PRECISE DAPT PARIS ischemic RS
nº of ischemic events in STEMI: 70 0.574  (0.488-0.659) 0.629  (0.558-0.701)
Discrimination capacity (C-statistic) for MB risk prediction in NSTEACS patients 
PRECISE DAPT PARIS bleeding RS
nº of MB events in NSTEACS: 35 0.682 (0.597-0.767) 0.619 (0.524-0.713)
Discrimination capacity (C-statistic)  for ischemic risk prediction in NSTEACS patients 
PRECISE DAPT PARIS ischemic RS
nº of ischemic events in NSTEACS: 63 0.551 (0.473-0.628) 0.569  (0.489-0.650)
Discrimination capacity (C-statistic) for MB risk prediction in prasugrel patients 
PRECISE DAPT PARIS bleeding RS
nº of MB events in prasugrel treated 
pts: 25
0.623 (.504-.743) 0.586 (0.460-0.713)
Discrimination capacity (C-statistic)  for ischemic risk prediction in prasugrel patients 
PRECISE DAPT PARIS ischemic RS
nº of ischemic events in prasugrel 
treated pts: 49
0.525 (0.429-0.620) 0.639  (0.551-0.727)
Discrimination capacity (C-statistic) for MB risk prediction in ticagrelor patients 
PRECISE DAPT PARIS bleeding RS
nº of MB events in ticagrelor treated 
pts: 58
0.648 (0.576-0.719) 0.573 (0.499-0.6488)
Discrimination capacity (C-statistic)  for ischemic risk prediction in ticagrelor patients 
PRECISE DAPT PARIS ischemic RS
nº of ischemic events in ticagrelor 
treated pts: 84
0.585 (0.514-0.657) 0.574  (0.505-0.642)
Discrimination capacity (C-statistic)  for MB risk prediction in patients > 75 years 
PRECISE DAPT PARIS bleeding RS
nº of MB events in the 581 pts > 75 
years: 21 
0.621 (0.559 – 0.691) 0.603 (0.547 – 0.663)
Discrimination capacity (C-statistic)  for MB risk prediction in patients with serum creatinine > 1.5 mg/dl
PRECISE DAPT PARIS bleeding RS
nº of MB events in the 261 pts with 
serum creatinine > 1.5 mg/dl: 7
0.744 (0.626 – 0.864) 0.693 (0.587 – 0.803)
Table 2: C-statistic analysis for RSs accuracy for different subgroups of patients.
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Supplementary materials figure 1: variables comprising the PRECISE-DAPT bleeding risk score.
Supplementary Figure 2. Kaplan-Meier curves for BARC type 3 or 
5 bleeding. A) Using PRECISE-DAPT classification system, and B) 
using PARIS bleeding risk classifcation system.
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Supplementary materials figure 3. Kaplan-Meier curves for 
cardiovascular death. A) Using PRECISE-DAPT risk strata. B) Using 
PARIS bleeding RS risk strata. C) Using PARIS ischemic RS risk strata.




























Supplementary materials figure 4. Kaplan-Meier curves for Myocardial 
infraction/stent thrombosis. A) Using PRECISE-DAPT risk strata. B) Using 







































































Supplementary materials figure 6. Average daily difference between 
ischemic and bleeding events. A) Using PRECISE-DAPT B) Using PARIS 
bleeding RS risk. C) Using PARIS ischemic RS.   
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